Market closed

Omeros/$OMER

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Omeros

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Ticker

$OMER
Sector
Health Care
Trading on
NASDAQ

Industry

Pharmaceuticals
Headquarters
Seattle, United States

Employees

198
Website
www.omeros.com

Omeros Metrics

BasicAdvanced
$498M
-
-$2.27
1.48
-

$498M

1.48

$13.60

$2.61

981K

2.965

2.329

-265.152

-281.143

-6.07%

-26.87%

220.52%

-3.23

-3.23

-3.287

-813.21%

4.46%

What the Analysts think about Omeros

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Omeros stock.

Omeros Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Omeros Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Omeros News

AllArticlesVideos
Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

Benzinga·4 weeks ago
Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Business Wire·4 weeks ago
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $OMER

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Omeros stock?

Omeros (OMER) has a market cap of $498M as of January 15, 2025.

What is the P/E ratio for Omeros stock?

The price to earnings (P/E) ratio for Omeros (OMER) stock is 0 as of January 15, 2025.

Does Omeros stock pay dividends?

No, Omeros (OMER) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Omeros dividend payment date?

Omeros (OMER) stock does not pay dividends to its shareholders.

What is the beta indicator for Omeros?

Omeros (OMER) has a beta rating of 1.48. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.